With 6.69 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.14 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $1.66 whereas the lowest price it dropped to was $1.2801. The 52-week range on MYNZ shows that it touched its highest point at $16.04 and its lowest point at $1.30 during that stretch. It currently has a 1-year price target of $14.00. Beta for the stock currently stands at 0.24.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MYNZ was up-trending over the past week, with a rise of 2.56%, but this was down by -3.61% over a month. Three-month performance dropped to -20.00% while six-month performance fell -47.71%. The stock lost -62.96% in the past year, while it has lost -83.46% so far this year.
Float and Shares Shorts:
On 2025-09-15, short shares totaled 0.1 million, which was 223.0 higher than short shares on 1755216000. In addition to Mr. Guido Baechler as the firm’s CEO & Executive Director, Dr. Christopher Von Toerne P.M.P., Ph.D. serves as its Chief Operating Officer.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With MYNZ analysts setting a high price target of 14.0 and a low target of 14.0, the average target price over the next 12 months is 14.0. Based on these targets, MYNZ could surge 775.0% to reach the target high and rise by 775.0% to reach the target low. Reaching the average price target will result in a growth of 775.0% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$10.84 being high and -$10.84 being low. For MYNZ, this leads to a yearly average estimate of -$10.84.
